Promoted Content Promoted Content

X

Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rexmyelocel-T

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: REX-001

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $55.9 million Upfront Cash: Undisclosed

            Deal Type: Financing January 18, 2021

            Details:

            The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development for the treatment of CLTI.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imatinib Mesylate

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: AV-101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Incubator

            Deal Size: $72.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 06, 2020

            Details:

            Funding will advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH.